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Abstract
Members of the class O of forkhead box transcription factors (FOXO) have important roles in metabolism,
cellular proliferation, stress resistance, and apoptosis. The activity of FOXOs is tightly regulated by
posttranslational modification, including phosphorylation, acetylation, and ubiquitylation. Activation of cell
survival pathways such as phosphoinositide-3-kinase/AKT/IKK or RAS/mitogen-activated protein kinase
phosphorylates FOXOs at different sites which regulate FOXOs nuclear localization or degradation. FOXO
transcription factors are upregulated in a number of cell types including hepatocytes, fibroblasts,
osteoblasts, keratinocytes, endothelial cells, pericytes, and cardiac myocytes. They are involved in a
number of pathologic and physiologic processes that include proliferation, apoptosis, autophagy,
metabolism, inflammation, cytokine expression, immunity, differentiation, and resistance to oxidative
stress. These processes impact a number of clinical conditions such as carcinogenesis, diabetes,
diabetic complications, cardiovascular disease, host response, and wound healing. In this paper, we focus
on the potential role of FOXOs in different disease models and the regulation of FOXOs by various stimuli.
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Members of the class O of forkhead box transcription factors (FOXO) have important roles in metabolism, cellular proliferation,
stress resistance, and apoptosis. The activity of FOXOs is tightly regulated by posttranslational modification, including
phosphorylation, acetylation, and ubiquitylation. Activation of cell survival pathways such as phosphoinositide-3-kinase/AKT/IKK
or RAS/mitogen-activated protein kinase phosphorylates FOXOs at different sites which regulate FOXOs nuclear localization
or degradation. FOXO transcription factors are upregulated in a number of cell types including hepatocytes, fibroblasts,
osteoblasts, keratinocytes, endothelial cells, pericytes, and cardiac myocytes. They are involved in a number of pathologic and
physiologic processes that include proliferation, apoptosis, autophagy, metabolism, inflammation, cytokine expression, immunity,
differentiation, and resistance to oxidative stress. These processes impact a number of clinical conditions such as carcinogenesis,
diabetes, diabetic complications, cardiovascular disease, host response, and wound healing. In this paper, we focus on the potential
role of FOXOs in different disease models and the regulation of FOXOs by various stimuli.

1. Introduction
The forkhead transcription factor family is characterized by
a winged-helix DNA binding motif and the forkhead domain
[1]. The mammalian forkhead transcription factors of the O
class (FOXOs) have four members: FOXO1, FOXO3, FOXO4,
and FOXO6. FOXO1 and FOXO3 are expressed in nearly all
tissues. FOXO4 is highly expressed in muscle, kidney, and
colorectal tissue while FOXO6 is primarily expressed in the
brain and liver [2].
Over the last decade, studies have demonstrated that
FOXOs play critical roles in a wide variety of cellular
processes. FOXOs transcriptionally activate or inhibit downstream target genes, thereby playing an important role in
proliferation, apoptosis, autophagy, metabolism, inflammation, differentiation, and stress resistance (Table 1). Deletion
of FOXOs has given insight into their function. Global
deletion of FOXO1 is lethal; it causes embryonic cell death
due to incomplete vascular development [3]. Global deletion
of FOXO3 is not lethal but affects lymph proliferation,

widespread organ inflammation [4], age-dependent infertility [3], and decline in the neural stem cell pool [5].
Global deletion of FOXO4 exacerbates colitis in response to
inflammatory stimuli [6]. Global deletion of FOXO6 displays
normal learning but impaired memory consolidation [7].

2. Regulation of FOXO Activity
FOXO transcriptional activity is regulated by a complex
array of posttranslational modifications. These modifications can be either activating or inactivating. They alter
nuclear import and export steps, modify the DNA binding affinity, and alter the pattern of transcriptional activity for specific target. FOXOs share significant sequence
homology and possess four distinct functional motifs which
include a forkhead, nuclear localization, nuclear export,
and transactivation domains (Figure 1). These domains are
highly conserved. FOXO1 and FOXO3 proteins are larger
(greater than 650 amino acids) than FOXO4 and FOXO6,
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Table 1: Cellular functions regulated by FOXO transcription factors.

FOXO

Cellular function

FOXO1, FOXO3, and FOXO4

Proliferation (−/+)

FOXO1, FOXO3, and FOXO4

Apoptosis (+/−)

FOXO1, FOXO3

Metabolism (+)

FOXO3

Differentiation (+/−)

FOXO1, FOXO3

Oxidative stress (-)

FOXO1, FOXO3

Atrophy (+)

FOXO1

Inflammation (+)

DAF-16, FOXOs

Aging (−)

DAF-16, FOXO3

Reproduction (−)

Pathway or target
G1-S phase entry, G2-M cell cycle
Extrinsic and intrinsic apoptotic
pathways
Glucose-6-phosphatase
Phosphoenolpyruvate carboxykinase
PGC1
Apolipoprotein C-III
B cell translocation gene 1
DNA binding 1
Myostatin, neurogenin 3, and
NK homeobox factor 6.1
Glutathione, selenoprotein P, manganese
superoxide dismutase, and peroxiredoxin
III
Gabarapl1, Atg12, calcineurin/nuclear
factor, and atrogin-1
IL-1𝛽, IL-6, IL-12, and Tlr4
P53, SIRT1, NF-𝜅B, MnSOD, heat-shock
proteins, and antimicrobial agents
Cell cycle inhibitor p27 enzyme
galactose-1-phosphate uridyltransferase
(Galt)
Prostaglandins

Reference
[2, 11]
[12–15]

[2]

[16–18]

[19–23]
[24, 25]
[26–30, 30]
[31–33]

[34, 35]

Listed are cellular functions and related transcriptional targets or pathways that have been reported to be directly regulated by FOXO transcription factors. The
effect of FOXO is depicted by increasing (+) or decreasing (−) the indicated cellular activity.

which are closer to 500 amino acids. FOXOs recognize two
response elements: Daf-16 family member binding element
(5 -GTAAA(T/C)AA) and insulin-responsive element (5 (C/A)(A/C)AAA(C/T)AA). The core DNA sequence 5 (A/C)AA(C/T)A-3 is recognized by all FOX-family members. Although FOXOs recognize both Daf-16 family member
binding element and the insulin response element, they
have a higher affinity for the former [8]. The transport
of FOXO proteins through the nuclear pore is dependent
on active-transport mechanisms. The presence of a nuclear
localization sequence is a prerequisite for maintaining proteins in the nucleus, whereas a nuclear export sequence
maintains proteins in the cytosol. FOXO proteins have both a
nuclear localization sequence and a nuclear export sequence
within the C-terminal DNA binding domain. Kinases and
interactions with other proteins modulate the effectiveness
of these nuclear localization sequences and nuclear export
sequences, which forms the basis of FOXO shuttling in and
out of the nuclear compartment. The cytoplasmic sequestration of FOXO proteins is mediated by a combination of
binding partners and changes in the properties of FOXO.
The chaperone protein 14-3-3 binds to FOXO factors in the
nucleus and allows their active export [9]. It also blocks the
nuclear localization signal to prevent FOXO re-entry into the
nucleus [10].

2.1. Phosphorylation. FOXOs are targeted for phosphorylation by several protein kinases, which modify different sites

FOXO1

FOXO3
FOXO4
FOXO6
Forkhead domain
Nuclear localization

Nuclear export
Transactivation

Figure 1: Regulatory motifs of FOXO1 (655aa), FOXO3 (673aa),
FOXO4 (505aa), and FOXO6 (492aa). The functional domains
are indicated: forkhead domain (teal), nuclear localization
(brown/gray), nuclear export (red), and transactivation (pink).

on FOXOs that alter their subcellular location, DNA binding affinity, and transcriptional activity [36, 37]. The PI3K
pathway is an important regulator of FOXO activity. The
serine-threonine kinases, protein kinase B (AKT), and
serum/glucocorticoid inducible kinase (SGK) are important downstream components of insulin/PI3 kinase pathway
[38]. AKT/SGK protein kinases phosphorylate FOXO1 and
FOXO3 at well-defined sites, which increase the association
with 14-3-3 proteins. This in turn results in the translocation of FOXO proteins from the nucleus to cytoplasm
leading to their transcriptional inactivation [39]. Growth
factor-activated protein kinases such as casein kinase 1 also
phosphorylate and potentiate FOXO1 export to the cytoplasm
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by directly increasing the interaction between FOXO and
the export machinery and Ran and Exportin/Crm1 [40, 41].
These also include extracellular signal-regulated kinase, IkB
kinase beta, and cyclin-dependent kinase 2. Other protein
kinases function to promote nuclear localization and increase
FOXOs transcriptional activity. These include JNK, p38,
AMPK, cyclin-dependent kinase 1, and macrophage stimulating 1. The increased nuclear localization is accomplished
in part by disrupting FOXO binding to 14-3-3 proteins [37].
FOXO6 is primarily localized to the nucleus as it lacks
the C-terminal AKT phosphorylation site. Phosphorylation
of FOXO by AKT also disrupts FOXO interactions with
DNA. The phosphorylation of FOXO at the second of the
three AKT/SGK sites (S256 for FOXO1) introduces a negative charge in the positively charged DNA-binding domain,
thereby inhibiting DNA binding. FOXO1 is also regulated
through the insulin signaling substrates 1 and 2 of the insulin
signaling cascade [38]. During insulin stimulation, FOXO1 is
phosphorylated by AKT and accumulates in the cytosol [38].
2.2. Acetylation. Similar to phosphorylation, acetylation has
been shown to both promote and decrease FOXO transcriptional activity and to mediate different biological functions
of FOXOs [36, 37]. The effect of acetylation on FOXOs
is controlled by the histone acetyltransferase and histone
deacetylases. Several lysines are acetylated in FOXOs. FOXO3
is acetylated at K242, K259, K271, K290, and K569 in the
presence of stress stimuli. Acetylation at K222, K245, K248,
K262, K265, K274, and K294 of FOXO1 was also reported
to regulate its DNA binding affinity and sensitivity to AKT
phosphorylation. Acetylation at K242, K245, and K262 of
FOXO1 is sufficient to attenuate its transcriptional activity.
Deacetylation at K186, K189, and K408 by histone deacetylases plays an important role in regulating FOXO4 transcriptional activity. It is reported that more highly acetylated forms
of FOXO3 favor expression of proapoptotic genes, (Bim,
TRAIL, and FasL), while the more deacetylated forms favor
expression of antioxidant and cytoprotective genes. FOXO
DNA binding activity is reduced by acetylation and enhanced
by deactylation [36, 37, 42, 43]. The binding of CREB binding
protein (CBP) and its paralog p300 to FOXOs is essential
for transactivation of target genes. However, the acetylation
itself attenuates FOXO transcriptional activity [36, 37]. In
FOXO1, CBP induced acetylation at two basic residues,
Lys242 and Lys245 located in the C-terminal region of the
DNA binding domain, has been shown to reduce its DNA
binding affinity and transcriptional activity [44]. Moreover
reactive oxygen species stimulate formation of cysteinethiol disulfide-dependent complexes between FOXO4 and
p300/CBP acetyltransferase, which reduces FOXO4 induced
cell cycle arrest and enhances FOXO4 induced apoptosis [45].
Silent information regulator 2 belongs to the sirtuin family
of NAD-dependent deacetylases, which respond to metabolic
changes in the cellular environment, including the availability
of nutrients/energy, and stress stimuli [46]. Sirt1 binds to
FOXOs and catalyze its deacetylation in an NAD-dependent
manner and thereby increase its transactivation activity by
regulating its DNA binding at specific target genes [42].
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2.3. Ubiquitination. Ubiquitination also plays a dual role in
the regulation of FOXO proteins. FOXO, like many other
proteins, is targeted for proteasome degradation through
polyubiquitination. Several ubiquitin E3 ligases are necessary
for the ubiquitination of FOXOs [39], which leads to FOXO1
degradation. In contrast proteasome inhibitors can block this
degradation and increase FOXO expression [47]. Elevated
SKP2 (an oncogenic subunit of the Skp1/Cul1/F-box protein
ubiquitin complex) levels are found in a wide variety of
human cancers, which can recognize the Ser256 phosphorylated FOXO1 and degrade it by polyubiquitination [48]. In
addition to this canonical role for ubiquitination in protein
degradation, monoubiquitination also plays a role in FOXO
regulation. Monoubiquitination of FOXOs has the opposite
effect and increases FOXO nuclear localization and induced
transcription activity [49]. For example, oxidative stress
stimulates relocalization of FOXO4 into the nucleus and the
subsequent activation of FOXO-dependent transcription by
inducing the monoubiquitination of FOXO4 at K199 and K211
[43, 50, 51]. Another mechanism is a ROS induced formation
of a complex of FOXO4 and the nuclear import receptor
transportin-1 that facilitates nuclear localization [52].
2.4. Interaction of FOXOs with Protein Partners. FOXOs can
associate with a variety of protein partners, activating or
repressing diverse target genes. The transcription factors and
the co-activators expressed in a particular cell type are thus
critical in determining the functional FOXO activity. FOXOs
themselves may regulate expression of target genes without
directly binding to DNA. For example it has been shown by
overexpression that a FOXO mutant which lacks DNA binding activity was still able to regulate target gene expression.
This result suggests that FOXO may regulate a subset of target
genes through interaction with other transcription factors.
It is also possible that this result reflects FOXO1 activity
only when pharmacologic levels of FOXOs are present by
overexpression [53]. In some cases FOXOs bind to other
factors to regulate downstream transcription activity. For
example, FOXO3 and Runx3 interact and bind concomitantly
to the promoter of Bim to promote apoptosis. The interaction
of Runx3 and FOXO3 is indispensable for Bim expression and
apoptosis in mouse embryonic fibroblasts and gastric cancer
cells [54]. In another example FOXO proteins have been
shown to interact with 𝛽-catenin. It has been suggested that
when FOXO1 binds to 𝛽-catenin, 𝛽-catenin is not available
to bind to T cell factor, thus reducing T cell factor activity
[55]. Thus, FOXO1 competes with T cell factor for 𝛽-catenin
and negatively impacts the capacity of 𝛽-catenin to stimulate
bone formation.
2.5. Regulation of FOXO1 by TNF-𝛼. Tumor necrosis factoralpha (TNF-𝛼) is a potent proinflammatory and proapoptotic
mediator that plays an important role in several normal
and disease processes by activating several different signaling
pathways. FOXO1 is strongly activated by TNF-𝛼 both in
vitro and in vivo [12]. In a chronic low-grade inflammatory
environment, FOXO1 activates the C/EBP𝛽 gene transcription through directly binding to its promoter in adipocytes,

4
thereby increasing the proinflammatory genes expression
such as MCP-1 and IL-6 [26]. This binding is inhibited after
insulin stimulation. However, the recruitment of FOXO1 onto
the C/EBP𝛽 gene promoter in the presence of insulin is
partially restored by pretreatment with TNF-𝛼 [26]. TNF𝛼 also enhances FOXO1 activity by reducing an inhibitory
signal. TNF-𝛼 inhibits AKT-mediated phosphorylation of
FOXO1 in adipocytes by reducing phosphorylation of insulin
receptor substrate-1 on tyrosine residues thereby diminishing
the negative effect of insulin receptor signaling [26].
2.6. Upstream Regulation of FOXO1 by LPS. Lipopolysaccharide (LPS) is a proinflammatory bacterial virulence factor
found in the cell wall of Gram-negative bacteria. LPS stimulates FOXO expression, nuclear localization, and FOXOmediated gene transcription. LPS induced inflammatory
cytokine expression is mediated, in part through FOXO
transcription factors [27]. LPS treatment impairs the ability
of insulin to phosphorylate FOXO1 in cultured macrophages.
FOXO1 activity may explain the abnormal production of
proinflammatory cytokine IL-1𝛽 and in conditions where
there is insulin resistance [27]. FOXO1 promotes inflammation by enhancing Tlr4-mediated signaling in mature
macrophages in response to LPS. However, LPS signaling
induces Akt, which leads to rapid phosphorylation and
nuclear export of FOXO1. While FOXO1 increases Tlr4mediated inflammatory signaling, the Tlr4-PI3K-AKT pathway in turn inactivates FOXO1 transactivation and limits
the inflammatory response. Insulin signaling increases AKT
activity to further reduce FOXO1 activation. This negative
feedback represents a self-limiting mechanism that contributes to the overactivation of the innate immune response
[56]. Thus, in cells where there is insulin resistance, this
inhibitory component is reduced. FOXO1 overstimulation of
inflammation is also modulated by a feedback mechanism
involving the mTOR pathway [56]. Rictor, a key component
of mTORC2, plays a role in controlling the inflammatory
response by reducing FOXO1 activation by LPS. These findings suggest that mTORC2 activates a negative feedback
loop after LPS stimulation to suppress FOXO1, which limits
inflammatory cytokine expression [56].
2.7. Cooperative Regulation of Inflammatory Genes by NF-𝜅B
and FOXO1. FOXO1 plays a cooperative role in inflammatory
signaling through NF-𝜅B. This cooperation couples proinflammatory cytokine production with insulin resistance and
is thought to contribute to greater inflammatory signaling
in obesity and type 2 diabetes [27]. Macrophage production
of IL-1𝛽 is governed by NF-𝜅B [57, 58]. NF-𝜅B in the active
state consists of a dimer and in the inactive state a trimer that
contains the active dimer plus an inhibitor I𝜅B subunit. In
the presence of inflammatory stimuli, I𝜅B is phosphorylated
and dissociates from the active NF-𝜅B dimer, which then
translocates to the nucleus to promote inflammation [58].
Several genes such as the IL-1𝛽 promoter contain both
FOXO1 and NF-𝜅B response elements. FOXO1 enhances
IL-1𝛽 expression when the NF-𝜅B dimer simultaneously
binds to its response elements. Both FOXO1 and NF-𝜅B
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are needed to induce IL-1𝛽 transcription. When FOXO1 is
inhibited by insulin signaling, expression of IL-1𝛽 is reduced.
When insulin signaling is reduced, the level of inflammation
increases because of greater FOXO1 binding to the promoter
sites of inflammatory genes. Thus, FOXO1 acts to amplify NF𝜅B induced inflammation and inflammation is reduced if this
amplifying component is inhibited [59, 60]. For the chemotactic ligand CCL20, it is found that FOXO1 overexpression
increases binding of the active NF-𝜅B dimer, while FOXO1
silencing decreases NF-𝜅B binding to its response element.
Since FOXO1 does not bind CCL20 promoter directly, it is
proposed that FOXO1 may serve as a coactivator of NF-𝜅B
in the nucleus to amplify NF-𝜅B signaling [28]. Thus, in
some cases such as IL-1𝛽, FOXO1 binds to a response element
nearby the NF-𝜅B binding element to enhance transcription, whereas, in CCl20, FOXO1 is thought to physically
interact with NF-𝜅B and enhance NF-𝜅B induced CCL20
transcription. In cases where there is deficient inhibition
of FOXO1 through insulin resistance, inflammation may
be enhanced by greater cooperation between NF-𝜅B and
FOXO1. However, in a colonic injury and inflammation
model, it was also found both in vivo and in vitro that FOXO4
inhibits the transcriptional activity of NF-𝜅B by reducing its
DNA binding activity [6].

3. FOXO1/FOXOs and Their
Clinical Significance
FOXO1 is the best-studied member of FOXO subfamily. Loss
and gain of FOXO1 function have been investigated in the
tissues and cells of various genetically modified mice of
different disease models (Figure 2).
3.1. Gluconeogenesis. Under fasting conditions, the liver provides energy by releasing glucose into the bloodstream.
Gluconeogenesis is regulated over the long term primarily through alterations in the expression of three major
gluconeogenic enzymes: G6Pase, fructose-1,6-biphosphatase,
and PEPCK [61]. PEPCK is the rate-limiting enzyme that
phosphorylates oxaloacetate to form phosphoenolpyruvate,
whereas G6Pase promotes the dephosphorylation of glucose6-phosphate, allowing for the release of newly synthesized
glucose into the bloodstream. Chronic expression of an
active FOXO1 mutant in the liver of transgenic mice leads
to increased expression of genes described above that are
involved in gluconeogenesis, resulting in elevated plasma
glucose levels. A major regulator of G6Pase and PEPCK,
and consequently gluconeogenesis, is PGC1𝛼 [62]. FOXO1
interacts with PGC1𝛼, thereby increasing the expression
of G6Pase and PEPCK. Transgenic mice that overexpress
FOXO1 have an impaired ability to regulate blood glucose
levels [63]. Liver-specific inactivation of the FOXO1 gene
reduces glucose levels because of decreased hepatic glucose
production [64]. Dominant-negative inhibition of FOXO1
in mice also decreases fasting blood glucose levels by suppressing the expression of the gluconeogenic genes G6Pase
and PEPCK [65]. In the fed state, transcription of FOXO1
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Gluconeogenesis
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Fracture healing
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Figure 2: Explanation of FOXO1 clinical significance. FOXO1 is the best-studied member of FOXO subfamily. FOXO1 function has
been investigated in the tissues and cells of various genetically modified mice of different disease models such as diabetic complications,
cardiomyopathy, and carcinogenesis. FOXO1 has been shown to enhance or diminish the clinical events either based on animal studies or
projection from in vitro studies.

dependent genes is antagonized by insulin induced AKT
phosphorylation [66].
3.2. Insulin Sensitivity and Lipid Metabolism. FOXO1 functions as a negative transcriptional modulator of insulin
sensing genes, which reduces insulin sensitivity. Conditional
deletion of FOXO1 in insulin-resistant mutant mice restores
insulin sensitivity and rescues the diabetic phenotype by
reducing hepatic expression of gluconeogenic genes (e.g.,
G6pc and Pck1) and by increasing adipocyte expression of
insulin-sensitizing genes (e.g., PPAR𝛾, Lep, and Slc2a4) [67].
The transcription factor pancreatic and duodenal homeobox
1 (Pdx1) plays a crucial role in 𝛽-cell growth and function. It
is regulated by another forkhead transcription factor, FOXA2.
FOXO1 and FOXA2 share common DNA binding sites in the
Pdx1 promoter. FOXO1 competes with FOXA2 for binding to
Pdx1 promoter, resulting in inhibition of Pdx1 transcription
[68]. Overexpression of constitutively active FOXO1 targeted
to the liver and pancreatic 𝛽-cells results in diabetes arising
from a combination of increased hepatic glucose production
and inhibited 𝛽-cells compensatory growth due to decreased
Pdx1 expression [67]. FOXO1 in osteoblasts has also been
linked to regulation of serum glucose levels. It has been
proposed that deletion of FOXO1 in osteoblasts increases
insulin sensitivity and insulin production through increased
osteocalcin expression and decreased expression of Esp
[69]. Patients with diabetes suffer disproportionately from
impaired lipid metabolism and FOXO1 controls aspects of
lipid metabolism in the diabetic liver. FOXO1 ablation in the
liver increases serum levels of very low density lipoproteins,
cholesterol, and plasma free fatty acids, three hallmarks
of the diabetic condition [70]. These findings suggest that
FOXO1 can protect against excessive hepatic lipid production
during hyperglycemia and may indicate that insulin treatment, which inhibits FOXO1, may indirectly worsen lipid
abnormalities in diabetics [70].
3.3. Diabetic Complications. Patients with diabetes have an
increased risk of developing a number of serious health
problems such as retinopathy and impaired fracture. It has

been proposed that diabetes-enhanced activation of FOXO1
is associated with several diabetic complications. FOXO1
promotes diabetic retinopathy by increasing apoptosis in
microvascular endothelial cells and pericytes [29]. In vivo
experiments indicate that diabetes increases FOXO1 mRNA
levels, DNA binding activity, and nuclear translocation mediated by TNF-𝛼 in retinal microvascular cells. Knockdown
of FOXO1 by siRNA in vivo diminishes the loss of retinal microvascular endothelial cells and pericytes, the first
step in diabetic retinopathy [29]. In vitro mRNA profiling
suggests that FOXO1 mediates high-glucose induced mRNA
expression of genes that modulate endothelial cell activation
such as CCL2 and CCL5, enhances apoptosis by increasing
mRNA levels of BCL2 and CASP3, and increases the basal
expression of genes that affect angiogenesis such as ITGA5
and ITGAV-M [29]. In vitro TNF-𝛼 and an advanced glycation end-product, which are elevated in diabetic retinopathy,
induce pericyte apoptosis through activation of the transcription factor FOXO1 [13].
FOXO1 has been linked to impaired diabetic fracture
healing. In vivo experiments demonstrate that diabetes
enhances FOXO1 DNA binding activity and increases FOXO1
nuclear translocation in chondrocytes [14]. Studies suggest
that this in turn causes expression of inflammatory and
resorptive factors leading to greater loss of cartilage in
diabetic fractures [14]. In vitro FOXO1 mediates TNF-𝛼
induced expression of proosteoclastogenic factors in chondrocytes (TNF-𝛼, RANKL, M-CSF, IL-1𝛼, and IL-6) and the
chemokine CCL4, which is linked to a burst of osteoclast
activity and accelerated loss of cartilage in diabetic fractures
[14, 71]. FOXO1 also promotes TNF-𝛼 induced apoptosis
and upregulates proapoptotic genes in chondrogenic cells
including caspase-3, caspase-8, caspase-9, and TRAIL [72].
3.4. Wound Healing. FOXO1 plays a positive role in wound
healing in normal mice [19] (Figure 3). It coordinates the
response of keratinocytes to wound healing through upregulation of TGF-𝛽1 and its downstream targets, integrin-𝛼3 and
-𝛽6, and MMP-3 and -9 which are needed for keratinocyte
migration. FOXO1 also functions in keratinocytes to reduce
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stress
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Integrin-𝛽6
Apoptosis
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Proliferation

Migration

Wound healing
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Figure 3: Mechanisms of FOXO1 in normal wound healing. The normal wound healing process is initiated by the integration of multiple
intercellular signals (cytokines and chemokines) released by keratinocytes and other cells. FOXO1 is required for keratinocyte transition to
a wound-healing phenotype. FOXO1 in vivo is needed for keratinocyte expression of transforming growth factor-𝛽1 (TGF-𝛽1) expression,
induction of TGF𝛽1 downstream targets (integrin-𝛼3 and -𝛽6 and MMP-3 and -9), and migration. Migration (bold arrow) is particularly
important in wound healing. FOXO1 is also needed to protect keratinocytes from oxidative stress, which contributes to keratinocyte migration
and survival during normal wound healing. This is adapted from [19].

oxidative stress that is necessary to maintain cell migration
and prevent cell death in a TGF𝛽1 independent manner.
However, in the diabetic wounds, FOXO1 has been linked to
impaired wound healing. In diabetic wounds FOXO1 DNA
binding activity and nuclear translocation are driven by
TNF-𝛼 and associated with higher levels of apoptosis and
reduced proliferation of fibroblasts [73, 74]. In vitro experiments suggest that FOXO1 may negatively affect fibroblasts
through expression of proapoptotic factors [12].

3.5. Cardiomyopathy. Autophagic vacuoles are found in cardiomyocytes in ischemic [75] and in cardiomyopathic failing
hearts [76]. Autophagy may also mediate the regression of
cardiac hypertrophy [77]. It is an evolutionarily conserved
process for the degradation of cytoplasmic components.
Autophagy may play a protective role under some circumstances but also may have a causative role in cell death.
Several reports confirm that FOXO1 plays both a positive
and negative role in autophagy related cardiomyopathy. In
vivo experiments establish the fact that cellular stress such
as ischemia/reperfusion induces autophagy in the heart
with concomitant increased nuclear localization and FOXO
activity [78]. FOXO1 can induce autophagy and reduce
cardiomyocyte cell size in vitro by binding to promoter
sequences of autophagy pathway genes Gabarapl1 and Atg12
and induce their expression [24]. FOXO1 also mediates
regression of cardiac hypertrophy by affecting autophagy
[79]. FOXOs reduce cardiac hypertrophy by inhibiting the
calcineurin/nuclear factor of activated T cells pathway, which
is a key signaling cascade that promotes cardiac hypertrophy
[25].

3.6. Carcinogenesis. FOXO1 acts as a tumor suppressor. Inactivation of FOXO1 has been documented in many types of
human cancer. FOXO1 activation inhibits tumor cell survival
by inducing apoptosis in prostate cancer and glioma cells
through upregulating proapoptotic factors [80, 81]. Prostate
cancer patients with regional lymph node involvement often
experience disease progression to other organs, with the bone
as the predominant site [82]. Increased FOXO1 activation
may limit the metastasis of the prostate cancer cells to other
organs by inhibiting the migration and invasion through
inhibition of Runt-domain containing protein Runx2 transcriptional activity [83]. Runx2 is normally expressed in
mesenchymal cells committed to the lineage of osteoblasts.
However, it should be noted that under some conditions
FOXO1 can induce the expression of genes that impart
resistance to chemotherapy [84].
Compared to a single deletion, deletion of multiple
FOXOs creates a more severe susceptibility to thymic lymphomas and hemangiomas. In vivo experiments demonstrate
that the lymphomas display an enrichment of the null alleles
for three FOXO genes accompanied by a marked decrease of
FOXO expression. There is reduced formation of lymphomas
in genotypes that retain at least one active FOXO allele. In
addition, complete loss of FOXO gene function in thymocytes
predisposes to lymphomagenesis through mechanisms that
enhance cellular proliferation and survival [85].
3.7. Oxidative Stress. FOXO1 plays an important role in
protection of cells against oxidative stress. Under normal
conditions FOXO1 induces expression of antioxidant genes to
decrease apoptosis [20]. This function of FOXO transcription
factors is important in long term survival of hematopoietic
stem cells as shown by increased hematopoietic stem cell
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apoptosis with deletion of FOXO1, FOXO3, and FOXO4
[86]. Diabetes is caused by pancreatic 𝛽-cell failure. FOXO1
can protect 𝛽-cells against oxidative stress in the pancreas
[87]. Oxidative stress is also important in wound healing.
We have shown that in normal wound healing FOXO1
functions to reduce oxidative stress in keratinocytes that is
necessary to maintain cell migration and prevent cell death
[19]. In contrast, FOXO1 appears to promote cell death when
oxidative stress is more extreme such as in tissues that are
affected by diabetic complications [88]. In the latter, FOXO1
may have a destructive rather than a protective role [88].
3.8. Innate Immune Response. FOXO1 has been shown to
enhance inflammation. FOXO1 promotes inflammation by
increasing expression of several proinflammatory genes.
FOXO1 mediates expression of proinflammatory cytokines
in response to high glucose, TNF, and LPS stimulation
[88]. Macrophages from insulin-resistant obese db/db mice
have increased FOXO1 activation, which is associated with
elevated production of IL-1𝛽. Moreover, FOXO1 promotes
IL-1𝛽 expression by binding to the IL-1𝛽 promoter [27].
FOXO1 also increases Tlr4 expression [28]. Since FOXO1 is
inhibited by insulin, a reduction in insulin signaling will tend
to enhance FOXO1 activation and to promote inflammation.
This highlights the role of FOXO1 as a key molecular proinflammatory transcription factor in the context of obesity and
insulin resistance. In dendritic cells and embryo fibroblasts
FOXO1 mediates LPS stimulated IL-6 and IL-12 expression
but reduces IL-10 production [30]. We have recently found
that FOXO1 expression by dendritic cells is needed for
dendritic cell homing to lymph nodes and optimal induction
of an adaptive immune response to bacterial challenge (Dong
G. et al., unpublished data).
3.9. Adaptive Immunity. Naive T lymphocytes travel between
the bloodstream and secondary lymphoid organs. Several
molecules are required for this constitutive trafficking.
FOXO1 increases expression of receptors that control T cell
trafficking to secondary lymphoid organs tissues and include
L-selectin, EDG1, and EDG6, the chemokine receptor CCR7,
and the transcription factor Klf2 [89, 90]. Survival and
homeostasis of T cells are influenced by the IL-7. FOXO1
controls T cell tolerance and naive T cell homeostasis through
the induction of IL-7R expression. It binds to the promoter of
IL7r gene and may promote expression by interacting with
other nuclear factors (e.g., GABP and Gfi-1) [91]. FOXO1 also
regulates the homing of peripheral B cells through upregulation of L-selectin and regulates class-switch recombination
in peripheral B cells [92]. FOXO1 plays a role in T cells by
enhancing survival of CD8 memory T cells [93].
Regulatory T cells (Tregs) play an indispensable role
in maintaining immunological unresponsiveness to selfantigens and in suppressing excessive immune responses
deleterious to the host. Tregs are produced in the thymus.
Formation of Treg requires FOXO transcription factors that
regulate expression of the transcription factor FOXp3 [94].
FOXO1-deficient T cells stimulated in the presence of TGF-𝛽
are misdirected to a Th1 cell phenotype, demonstrating that
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FOXO1 is necessary for TGF-𝛽 induced differentiation of Treg
cells [94]. Moreover, these studies suggest that the absence of
FOXO1 through loss of Treg cells increases the likelihood of
autoimmunity.
3.10. Osteoblasts. Recent evidence suggests that FOXO factors play a fundamental role in skeletal homeostasis by upregulating antioxidant enzymes [11, 20]. Deletion of FOXO1 in
osteoblasts results in decreased expression of antioxidants
such as glutathione. Consistent with this, conditional deletion
of FOXO factors (FOXO1/3/4) in bone results in increased
oxidative stress, loss of osteoblasts, and decreased bone
mass indicating that FOXO factors are indispensable for
skeletal homeostasis because of their stimulation of antioxidant defense mechanisms [11, 20]. Moreover, the deletion
of multiple FOXOs has greater impact than deletion of
individual FOXOs. It has also been reported that FOXO1
deletion inhibits formation of a mineralized matrix in vitro
by osteoblastic cells and that FOXO1 interacts directly with
the Runx2 promoter [95]. Moreover, FOXO1 overexpression
increases the expression of osteogenic markers such as
Runx2, alkaline phosphatase, and osteocalcin indicative of
enhanced bone formation [96]. FOXO1 also promotes protein
synthesis in osteoblasts through direct regulation of ATF4,
a transcription factor required of amino acid import and
protein synthesis [11]. These results indicate that FOXO1 plays
an important role in promoting the differentiation or activity
osteoblasts, which is critical for bone formation.
In the previous examples, FOXO1 plays a positive role in
bone formation by enhancing differentiation or activity of
osteoblasts and protecting these cells through induction of
antioxidants. However, under other conditions, FOXO1 may
have a negative effect on bone by affecting Wnt signalling.
FOXOs can attenuate Wnt/𝛽-catenin signaling by diverting
𝛽-catenin from the nucleus [97]. In vivo deletion of FOXOs in
progenitors of osteoblasts and adipocytes increases osteoblast
numbers and bone mass. This is thought to occur by increasing proliferation of osteoprogenitor cells and enhancing
bone formation by reducing FOXO1 interference of Wnt/𝛽catenin signaling [97]. In addition, FOXO1 may contribute to
immune-mediated inhibition of bone formation by promoting apoptosis of osteoblasts [98]. Thus, the effects of FOXO
transcription factors on bone are complex and may depend
upon specific conditions.

4. FOXO3 and Its Clinical Significance
4.1. Cardiovascular Disease. Vascular smooth muscle cell
proliferation and migration contribute significantly to atherosclerosis, postangioplasty restenosis, and transplant vasculopathy. FOXO3 is thought to play a positive role in limiting
these diseases by inhibiting smooth muscle cell proliferation
and activation. In vivo overexpression of FOXO3 increases
p27 (kip1) in vascular smooth muscle cells and inhibits neointimal hyperplasia [99]. Cysteine-rich angiogenic protein 61
is an immediate early gene expressed in these cells upon
growth factor stimulation. Angiogenic protein 61 expression
is associated with postangioplasty restenosis. Both in vivo
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and in vitro experiments confirmed that FOXO3 inhibits
vascular smooth muscle cells proliferation and neointimal
hyperplasia by inhibiting the expression of cysteine-rich
angiogenic protein 61 through a FOXO binding motif in
the cysteine-rich angiogenic protein 61 promoter region
[100]. Similar to FOXO1, FOXO3 has been postulated to
play both a positive and negative role in autophagy related
cardiomyopathy such as ischemic and cardiac hypertrophy.
In vivo overexpression of FOXO3 reduces the cardiomyocyte
size by increasing autophagosome formation, expression of
atrogin-1, and autophagy-related genes (LC3, Gabarapl1, and
Atg12) [78, 101].
4.2. Carcinogenesis. In carcinogenesis, FOXO3 and FOXO1
both suppress tumor growth. Restoring the activity of FOXO3
promotes tumor cell death. For example, the anticancer
drugs such as STI571 and paclitaxel inhibit tumor growth by
increasing levels of Bim expression through upregulation of
FOXO3 in chronic leukemia cells and breast cancer cells [102,
103]. Another mechanism involves FOXO3 downregulation
of Myc. Since Myc enhances tumor cell proliferation and
survival, its downregulation by FOXO3 is antitumorigenic
[104]. In some cases FOXO3 has the opposite effect of
enhancing survival of drug-resistant tumor cells through its
antioxidant effect like that of FOXO1 in this process [105].
4.3. Oxidative Stress. Similar to FOXO1, FOXO3 also plays an
important role in protection of cells against oxidative stress.
FOXO3 increases the levels of manganese superoxide dismutase (MnSOD) in mitochondria, which removes superoxide
radicals. In vivo experiments suggestthat FOXO3 protects
against oxidative stress by increasing MnSOD expression and
production of catalase and peroxiredoxin III [21]. FOXO3
also protects erythropoiesis against oxidative stress [106] and
decreases oxidative stress in cardiac fibroblasts [22]. FOXO3
is the predominant FOXO isoform expressed in neural
stem/progenitor cells. Among the FOXO3-regulated genes
in neural stem/progenitor cells are antioxidants [107]. In
vitro experiments suggest that FOXO3 deletion in these cells
impairs two major metabolic modules (glycolysis and Gln
metabolism), which contribute to oxidative stress. FOXO3 is
also critical for hematopoietic self-renewal. In vivo experiments establish that FOXO3 deletion in hematopoietic stem
cells increases ROS and impairs their hematopoietic capacity
[108].
4.4. Adaptive Immunity. FOXO3 inhibits T cell proliferation and induces T cell apoptosis. FOXO3 induces T cells
apoptosis through upregulation of Puma and Bim after IL-12
withdrawal [109]. FOXO3 also suppresses T cell proliferation
and T cell activation, which has been shown to prevent
autoimmunity. In vivo deletion of FOXO3 leads to spontaneous lymph proliferation associated with inflammation,
which correlates with the presence of hyperactivated helper
T cells along with more production of Th1 and Th2 cytokines
[4]. FOXO3 also restrains the magnitude of T cell in immune
responses by inhibiting the capacity of dendritic cells to
produce IL-6 [110]. Similar to T cells, FOXO3 induces B cell
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apoptosis through upregulation of both proapoptotic genes
such as Bim and antiproliferative genes such as Rb2 [111].
FOXO3 also regulates FOXp3 expression that is needed to
generate Treg cells [112]. FOXO3 deficiency results in defective TGF-𝛽-driven FOXp3 induction. Thus, FOXO3 promotes
transcription of the FOXp3 gene in Treg cells similar to that
of FOXO1. In addition, the absence of FOXO3 exacerbates the
loss of Treg cell formation in mice with FOXO1 deletion [94]
so that the impact when both are absent is greater than the
loss of FOXO1 alone.
4.5. Aging and Reproduction. C. elegans is the most extensively studied organism in aging research and DAF-16, a homolog
of mammalian FOXO genes, affects longevity by extending C.
elegans lifespan [31]. In mammalian cells deletion of FOXO1
or FOXO3 limits expression of antioxidants to enhance oxidative stress and cell injury associated with aging. Extension
of cellular lifespan that depends upon the prevention of cell
senescence also may require the negative regulation of AKT
to allow for the activation of FOXO3 [32].
In recent years, a number of in vivo mouse genetic
experiments prove that FOXO3 functions in suppressing
the initiation of follicular growth and control reproductive potential. FOXO3 deletion results in early depletion
of the primordial follicle pool so that young female mice
have normal size litters but reach menopause more quickly.
Constitutively active FOXO3 expressed in transgenic mice
suppresses follicular maturation and largely prevents ovulation [34]. DAF-16/FOXO may also affect the delivery of
polyunsaturated fatty acids to oocytes which may influence
ovulation and reproduction [35].

5. FOXO4 and Its Clinical Significance
5.1. Diabetic Complications. Diabetic nephropathy is the
leading cause of renal failure. It is thought that hyperglycemia
activates multiple downstream signaling pathways in the
diabetic kidney, which contributes to the development of diabetic nephropathy [113]. Advanced glycation end-products
contribute to the development of diabetic nephropathy [114].
FOXO4 mediates podocyte apoptosis induced by advanced
glycation end-products by increasing the expression of the
proapoptotic gene Bim [115].
5.2. Cardiovascular Disease. During atherosclerosis, vascular smooth muscle cells migrate from the medial layer of
the blood vessel wall to the intimal layer, which requires
of the action of matrix metalloproteinases (MMPs) [116].
MMP9 is required for smooth muscle cell migration during
the development of restenotic and atherosclerotic lesions.
FOXO4 activates transcription of the MMP9 gene in response
to TNF-𝛼 signaling. Inhibition of FOXO4 expression reduces
the ability of vascular smooth muscle cells to migrate in vitro
and in vivo deletion of FOXO4 inhibits neointimal migration
of these cells associated with reduced MMP9 expression [117].
These studies suggest that FOXO4 is as a potential therapeutic
target for combating proliferative arterial diseases [117].
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5.3. Carcinogenesis. FOXO4 functions as a tumor suppressor
in the development and progression of cancer. The expression
of FOXO4 is significantly decreased or deleted in colorectal
cancer tissue [118]. Strong expression of HER2, a receptor tyrosine kinase oncogene in cancers, has been associated with a poor prognosis. Constitutively active FOXO4
can reduce tumor onset, size, and progression in nude
mice transplanted with Her2-positive breast cancer cells by
inhibiting AKT activity, regulating P27 kip1 stability and
suppressing HER2-mediated tumorigenicity [119]. FOXO4
can also inhibit growth factor-mediated tumor metastasis
in cholangiocarcinoma by enhancing ANXA8 expression,
which inhibits the migratory and metastatic characteristics of
cholangiocarcinoma cells [120].

the differentiation of Treg cells that play a critical role in
preventing autoimmune disease. FOXOs also enhance normal wound healing, protect against cardiovascular disease,
protect against oxidative stress associated with aging, protect
against ovarian follicle depletion, and have antitumor activities. FOXOs agonist in these situations may be beneficial. In
light of the different cellular functions, regulation of FOXO
transcription factors by antagonists in some disease states or
agonists in normal and disease conditions may be useful in
treating or preventing a wide variety of disorders. A further
understanding of their function will provide essential insight
into both basic and clinical processes.

6. FOXO6 and Its Clinical Significance

The authors declare that there is no conflict of interests
regarding the publication of this paper.

6.1. Neurons. FOXO6 can promote the development and
function of the adult central nervous system. Neuronal polarity is essential for normal brain development. FOXO6 plays a
critical role in axodendritic polarization of undifferentiated
neurites in a switch from unpolarized to polarized neuronal
morphology by increasing expression of the protein kinase,
Pak1 [121]. Memory consolidation is a process that stabilizes
memory after initial acquisition. FOXO6 promotes memory
consolidation in vivo by regulating neuronal connectivity
in the hippocampus. During learning FOXO6 induces the
expressions of genes that orchestrate proper synaptic number
and function leading to correct neuronal connectivity in the
hippocampus [7].
6.2. Gluconeogenesis. Similar to FOXO1, FOXO6 can promote gluconeogenesis, which is inhibited by insulin signaling. Elevated FOXO6 activity in the liver augments gluconeogenesis and raises fasting blood glucose levels through
increased G6pase expression. In contrast, hepatic FOXO6
depletion suppresses gluconeogenesis, resulting in fasting
hypoglycemia. Insulin inhibits FOXO6 activity by inducing
its phosphorylation and blocking its transcriptional activity.
FOXO6 becomes deregulated in the insulin-resistant liver,
accounting for its enhanced activity in promoting gluconeogenesis and correlating with the pathogenesis of fasting
hyperglycemia in diabetes [122].

7. Conclusion
FOXO transcription proteins modulate several cellular functions including proliferation, apoptosis, stress resistance,
inflammation migration, and metabolism through regulation
of multiple transcriptional targets. FOXO function has been
investigated in various disease models. In some diseases such
as diabetes or diabetic complications wound benefits from
inhibiting FOXOs since deletion or knockdown of FOXOs
has a positive effect. However, FOXOs also have protective
roles and can play an important role in differentiation, which
may be useful in promoting health. For example, FOXO
agonists could potentially be used to protect and prevent
loss of stem cells that diminish with aging. FOXOs promote
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